Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients.

Abstract

In a multicenter study of hemodialysis patients in Spain, the immunogenicity of a yeast-derived recombinant deoxyribonucleic acid hepatitis B vaccine was evaluated. Two different vaccination schedules were examined: zero, one, two, six months and zero, one, two, 12 months. Two different dose levels (20 micrograms and 40 micrograms) were also compared. No serious adverse effects were reported by any of the vaccinees; the most frequently reported reaction was soreness at the injection site. This study also indicated that higher concentrations of antibodies are attained when more frequent doses of vaccine are administered. The yeast-derived vaccine produced an immune response similar to that of the plasma-derived vaccines.

Cite this paper

@article{Bruguera1989ImmunogenicityOA, title={Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients.}, author={Miquel Bruguera and Manel Cremades and Jos{\'e} Louis Rodicio and Jos{\'e} Mar{\'i}a Alcazar and Armando Oliver and Giovanni Del Rio and Rafael Esteban-Mur}, journal={The American journal of medicine}, year={1989}, volume={87 3A}, pages={30S-32S} }